Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05158751

Acronym

MAVERIC

Enrollment

100

Registered

2021-12-15

Start date

2026-01-31

Completion date

2026-05-31

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocarditis, Premature Ventricular Contractions, Ventricular Tachycardia (VT)

Brief summary

To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.

Detailed description

Hypothesized that occult inflammation is clinically under-recognized in patients with symptomatic PVCs with and without Left ventricular (LV) dysfunction and can be a potential link between the 2 conditions. Aimed to evaluate the incidence of underlying inflammation using the Positron emission tomography (PET) scan in patients presenting with symptomatic PVCs enrolled retrospectively in the MAVERIC registry.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients \> 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours. * Non-sustained VT was defined as ≥3 more consecutive beats lasting \<30 seconds

Exclusion criteria

* History of myocardial infarction, * Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography, * History of revascularization, * Significant symptomatic atrial arrhythmias associated with LV dysfunction, * Severe valvular disease, * Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, * History of cardiac arrest, * History of channelopathies or inherited arrhythmias.

Design outcomes

Primary

Measure	Time frame	Description
Identify the underlying myocarditis in patients presenting with PVCs with or without reduced LVEF	Retrospective Collection between dates January 2014-January 2023	To identify the underlying myocarditis in patients presenting with PVCs with or without reduced LVEF through laboratory testing, FDG-PET(18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose - positron emission tomography) scan, Cardiac Magnetic Resonance imaging and/or Endomyocardial biopsy.

Secondary

Measure	Time frame	Description
Ascertain whether immunosuppressive therapy (IST) affords short term and long term improvement of LVEF and clinical outcomes	Retrospective Collection between dates January 2014-January 2023	To ascertain whether immunosuppressive therapy (IST) affords short term and long term improvement of LVEF and clinical outcomes in virus negative and FDG-PET positive patients with non-ischemic cardiomyopathy, myocardial inflammation and PVCs.

Other

Measure	Time frame	Description
Evaluate whether IST + catheter ablation results in optimal clinical response	Retrospective Collection between dates January 2014-January 2023	To evaluate whether IST + catheter ablation results in optimal clinical response in virus negative and FDG-PET positive patients with PVCs with or without reduced LVEF

Countries

United States

Contacts

Primary ContactDonita Atkins

datkins@kchrf.com816-651-1969

Outcome results